SGMT
NASDAQSagimet Biosciences Inc.
News25/Ratings12
News · 26 weeks53+175%
2026-03-012026-08-23
Mix3090d
- Insider15(50%)
- Other9(30%)
- SEC Filings6(20%)
Latest news
25 items- PRSagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4 2026. "We continue to advance the clinical development of denifanstat for acne and remain on track to enroll our first patient in AURORA in the fourth quarter of 2
- PRSagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees. The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensatio
- INSIDERDirector Kemble George exercised 350,987 units of Series A Common Stock at a strike of $6.36 and sold $3,591,580 worth of Series A Common Stock (350,987 units at $10.23) as part of a pre-agreed trading plan (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Sagimet Biosciences Inc.SCHEDULE 13G - Sagimet Biosciences Inc. (0001400118) (Subject)
- SECSEC Form 8-K filed by Sagimet Biosciences Inc.8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult PatientsFOSTER CITY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application and issued a "Study May Proceed" letter for the company’s Phase 3 clinical trial of fatty acid synthase (FASN) inhibitor denifanstat in moderate to severe acne. The Phase 3 clinical trial is on track to initiate in the second half of 2026. "This letter marks an important regulatory milestone for denifanstat," said Andreas Grauer, MD, Chief Medica
- INSIDERDirector Kemble George exercised 20,206 units of Series A Common Stock at a strike of $6.36 and sold $201,147 worth of Series A Common Stock (20,206 units at $9.95) as part of a pre-agreed trading plan (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSEC Form 10-Q filed by Sagimet Biosciences Inc.10-Q - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesPhase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured equity financing with gross proceeds of $175.0 million in April 2026 Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to severe acne FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing
- PRSagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth ConferenceFOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here). About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator o
- INSIDERPresident & CEO Happel David sold $497,068 worth of Series A Common Stock (64,051 units at $7.76), decreasing direct ownership by 8% to 741,570 units (SEC Form 4) (for tax liability)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERChief Legal & Admin. Officer Rozek Elizabeth sold $81,832 worth of Series A Common Stock (10,545 units at $7.76), decreasing direct ownership by 4% to 224,414 units (SEC Form 4) (for tax liability)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERDirector Kemble George sold $140,529 worth of Series A Common Stock (18,844 units at $7.46) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 62,161 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Joins the Russell 2000® and Russell 3000® IndexesSAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effective at the open of U.S. equity markets today, as part of the 2026 Russell Indexes reconstitution. The June reconstitution of the Russell US indexes captures up to the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for half a year beginning in 20
- PRSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in 1x1 investor meetings at the Leerink Partners Therapeutics Forum in Boston, MA on July 15, 2026. Inducement Grant In connection with the hiring of two employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 34,300 stock options, in aggregate to purchase shares of the Company’s Series A common stock, be granted on June 22, 2026 to the newly hired employees. The option
- INSIDERSEC Form 4 filed by Director Seidenberg Beth C4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoelscher Paul W.4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 4 filed by Director Jarrett Jennifer4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 4 filed by Director Grammer Elizabeth A4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 4 filed by Director Kemble George4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Anne M.4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
SGMT FAQ
6 questionsWhere does SGMT stock trade?
Sagimet Biosciences Inc. (SGMT) is listed on NASDAQ.What sector and industry is SGMT in?
Sagimet Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sagimet Biosciences Inc. go public?
Sagimet Biosciences Inc. (SGMT) completed its IPO in 2023.What are analysts saying about SGMT?
Sagimet Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $2800.00 price target on 2026-03-26. Recent price targets range from $800.00 to $3000.00.What companies are similar to SGMT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SGMT side-by-side with any of them on Quantisnow.How can I track SGMT on Quantisnow?
Quantisnow aggregates Sagimet Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SGMT to receive live email and push alerts on every new disclosure.